All In Biotech

Drug Trial Radar · NCT04671433

Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Dec 4, 2020

Primary completion

Sep 30, 2024

Study completion Sep 30, 2024

Sponsor

Lead sponsor
MeiraGTx Ocular UK LtdIndustry
Sponsor type
Industry
First posted
Dec 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)

Conditions

  • X-Linked Retinitis Pigmentosa

Interventions

  • Genetic: AAV5-hRKp.RPGRBiological

    Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group

  • Genetic: AAV5-hRKp.RPGRBiological

    No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 52 in Vision-guided Mobility Assessment (VMA) as Measured by the Ability of the Participant to Navigate Through a VMA MazeTime frame: From Baseline to 52 Weeks

Locations

28 sites in 11 countries. Site status is shown where the registry gives one.

  • Shiley Eye Institute Jacobs Retina Center

    La Jolla, California

  • Childrens Hospital

    Los Angeles, California

  • Stanford Health Care

    Palo Alto, California

  • VitreoRetinal Associates, PA

    Gainesville, Florida

  • Emory University

    Atlanta, Georgia

  • Massachusetts General Hospital - Center for Celiac Research and Treatment

    Boston, Massachusetts

  • Univ of Michigan Medical Center

    Ann Arbor, Michigan

  • Duke Eye Center

    Durham, North Carolina

  • University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, Pennsylvania

  • Retina Consultants of Houston

    Bellaire, Texas

  • UZ Gent

    Ghent, Belgium

  • Hospital For Sick Children

    Toronto, Ontario, Canada

  • Rigshospitalet Glostrup

    Glostrup Municipality, Denmark

  • Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts

    Paris, France

  • Hadassah Medical Center

    Jerusalem, Israel

  • Azienda Ospedaliero Universitaria Careggi

    Florence, Italy

  • Ospedale San Paolo

    Milan, Italy

  • Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli

    Naples, Italy

  • IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia ONLUS

    Roma, Italy

  • VUMC Amsterdam

    Amsterdam, Netherlands

  • Radboudumc

    Nijmegen, Netherlands

  • Hosp Univ Fund Jimenez Diaz

    Madrid, Spain

  • University Hospital Basel, Eye Clinic/Institute of Molecular and Clinical

    Basel, Switzerland

  • Universite de Lausanne, Hopital ophtalmique Jules-Gonin

    Lausanne, Switzerland

  • NHS Lothian

    Edinburgh, United Kingdom

  • Gartnavel General Hospital

    Glasgow, United Kingdom

  • St James University Hospital

    Leeds, United Kingdom

  • Moorfields Eye Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.